Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | ESRRG | P62508 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630764 | 0.91 | SOAT1 (0.46) | LTB4R2HTR2AKDM4EALDH1A1 | |
| SCHEMBL4630741 | 0.81 | LTB4R2 (0.46) | LTB4R2HTR2A | |
| SCHEMBL4764980 | 0.79 | FFAR4 (0.43) | POLBLTB4R2HTR2A | |
| Tert-Butylamine SCHEMBL5311320 | 0.78 | LTB4R2 (0.43) | LTB4R2HTR2A | |
| SCHEMBL4631178 | 0.76 | TSPO (0.53) | RIPK1KDM4EALDH1A1 | |
| SCHEMBL3963598 | 0.75 | PPARA (0.42) | LTB4R2 | |
| SCHEMBL4630408 | 0.75 | LTB4R2 (0.48) | LTB4R2HTR2A | |
| SCHEMBL3114200 | 0.74 | POLB (0.54) | POLBAPEX1TDP1LTB4R2ALDH1A1 | |
| SCHEMBL4631046 | 0.74 | PPARG (0.42) | POLBLTB4R2HTR2A | |
| SCHEMBL13267953 | 0.72 | POLB (0.51) | POLBAPEX1TDP1LTB4R2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517883-B8 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-05-21 | — | — | EP | disclosed |
| US-7355069-B2 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| EP-1517883-B1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20050256198-A1 | Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1517883-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | AstraZeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000790-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256198-A1 | Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance | GPR119, INSR, IRS1 | POLB 2492/4885APEX1 3815/4885TDP1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.